FDA Approves FoundationOne® CDx as Companion Diagnostic for Brigatinib

On July 1, 2021, the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx as a companion diagnostic for brigatinib, which is currently FDA-approved for the treatment of adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

Read the Foundation Medicine announcement.

Posted 7/1/2021